Zelluna Immunotherapy Overview

  • Founded
  • 2016

Founded

  • Status
  • Private

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

Zelluna Immunotherapy General Information

Description

Operator of a biopharmaceutical company intended to develop T-cell receptor (TCR) based cancer immunotherapy. The company's primary focus is to develop a portfolio of tumor-specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient, and durable, enabling patients who are currently lacking efficient treatments to get their required treatments, from a wide range of advanced technologies.

Contact Information

Website
www.zelluna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Oslo Cancer Cluster Innovation Park
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway

Zelluna Immunotherapy Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zelluna Immunotherapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 25-Aug-2022 00.000 Completed Generating Revenue
2. Early Stage VC (Series A) 11-Jun-2020 00.000 00.000 000.00 Completed Generating Revenue
1. Early Stage VC 01-Jan-2016 Completed Startup
To view Zelluna Immunotherapy’s complete valuation and funding history, request access »

Zelluna Immunotherapy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to develop T-cell receptor (TCR) based cancer immunotherapy. The compan
Drug Discovery
Oslo, Norway
26 As of 2023
00.000
0000000000 0 00.000

000000

trud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000 000000000
Saint-Julien- en-Genevois, France
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

r sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut lab
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zelluna Immunotherapy Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genkyotex Corporate Backed or Acquired Saint-Julien- en-Genevois, France 00 000.00 000000&0 000.00
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000 000000 Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Philadelphia, PA 00 00000 000000000 00000
0000000 000000000 Venture Capital-Backed Vienna, Austria 00 000.00 0000000000 0
You’re viewing 5 of 38 competitors. Get the full list »

Zelluna Immunotherapy Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Zelluna Immunotherapy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202303626-D0 Compositions and methods for immunotherapy Pending 13-Mar-2023

Zelluna Immunotherapy Executive Team (6)

Name Title Board Seat Contact Info
Namir Hassan Ph.D Chief Executive Officer
Geir Christian Melen Chief Financial Officer & Director of Finance
Anders Holm Ph.D Chief Operating Officer & Head, Business Development
Hans Ivar Robinson Co-Founder & Chairman
You’re viewing 4 of 6 executive team members. Get the full list »

Zelluna Immunotherapy Board Members (6)

Name Representing Role Since
Anders Tuv Radforsk Investeringsstiftelse Board Member 000 0000
Bent Jakobsen Ph.D Self Board Member 000 0000
Gustav Gaudernack Self Board Member 000 0000
Hans Ivar Robinson Self Co-Founder & Chairman 000 0000
Hans-Peter Bøhn Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Zelluna Immunotherapy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zelluna Immunotherapy Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
Birk Venture Venture Capital Minority 000 0000 000000 0
Radforsk Investeringsstiftelse Venture Capital Minority 000 0000 000000 0
Ro Invest Venture Capital Minority 000 0000 000000 0
To view Zelluna Immunotherapy’s complete investors history, request access »

Ready to get started?

Request a free trial